ABSTRACT
In this study the in vitro activities and pharmacodynamic properties of moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin were compared on recently isolated respiratory pathogens and strains of Streptococcus pneumoniae with known mechanisms of fluoroquinolone resistance. In addition, the resistance selection frequencies of moxifloxacin and levofloxacin on three recently isolated respiratory pathogens and four strains of S. pneumoniae with known mechanisms of fluoroquinolone resistance were investigated. The four fluoroquinolones had similar activities against both Moraxella catarrhalis (MIC(90)s 0.015-0.06 mg/L) and Haemophilus influenzae (MIC(90)s 0.008-0.03 mg/L). More marked differences in activity were noted with S. pneumoniae, with MIC(90)s of 0.25, 1, 0.5 and 0.03 mg/L for moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin, respectively. With the S. pneumoniae strains, the four fluoroquinolones exhibited similar concentration-dependent time-kill kinetics. The resistance selection frequencies of levofloxacin were higher than those of moxifloxacin at concentrations equivalent to those at the end of the dosing interval. Therefore moxifloxacin may have less of an impact on the development of resistance than levofloxacin.
Subject(s)
Anti-Infective Agents/pharmacology , Drug Resistance, Bacterial/physiology , Haemophilus influenzae/drug effects , Moraxella catarrhalis/drug effects , Streptococcus pneumoniae/drug effects , Fluoroquinolones , Haemophilus influenzae/isolation & purification , Humans , Microbial Sensitivity Tests/statistics & numerical data , Moraxella catarrhalis/isolation & purification , Streptococcus pneumoniae/isolation & purificationABSTRACT
The influence of protein binding upon different aspects of the in vitro activity of faropenem on recently isolated Staphylococcus aureus and respiratory pathogens was determined. The protein binding of faropenem was investigated in inactivated human serum and albumin by ultrafiltration. The effect of the presence of inactivated human serum and albumin on the in vitro activity of faropenem and amoxicillin was established and the influence of protein binding on the pharmacodynamic properties of faropenem and amoxicillin was compared. The protein binding of faropenem was 96% and 95% in pooled inactivated human serum and 99% and 98% in 45 mg/L human albumin, at 8 and 25 mg/L, respectively. The presence of inactivated human serum (20% and 70%) increased the mean faropenem MICs by two dilution steps and albumin increased the mean faropenem MICs by three dilution steps. The mean amoxicillin MICs were less affected than faropenem by the presence of either inactivated human serum or albumin. Faropenem and amoxicillin exhibited similar time-dependent kinetics. Faropenem was bacteriostatic on Moraxella catarrhalis, Haemophilus influenzae and group A streptococci, and bactericidal for Streptococcus pneumoniae (after 4 h with concentrations equivalent to 5 x and 10 x MIC) in Iso-Sensitest broth. In 70% inactivated human serum faropenem was slowly bactericidal against M. catarrhalis, H. influenzae (one strain) and S. pneumoniae (one strain) but not group A streptococci and the other S. pneumoniae strain. A significant inoculum effect was observed with all strains except S. pneumoniae. Both faropenem and amoxicillin appeared more active in 70% inactivated human serum than in Iso-Sensitest broth.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Lactams , Serum Albumin/metabolism , Amoxicillin/metabolism , Amoxicillin/pharmacokinetics , Anti-Bacterial Agents/metabolism , Humans , Microbial Sensitivity Tests/statistics & numerical data , Protein Binding/drug effects , Protein Binding/physiology , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/metabolism , beta-LactamsABSTRACT
In this study the Oxoid Aura image antibiotic sensitivity test system, used as a stand-alone device, was compared with manual zone measurement and use of a template, for the determination of sensitivities. An overall correlation coefficient of 0.99 was observed for zone diameters measured using the Aura image system and zones measured manually, when the differences between zones were within 3 mm; 5.4% of zones showed a difference in zone diameter between manual and automated measurement of >3 mm. The results obtained using the template method for interpretation were less reliable than zone measurement, with cefuroxime and ampicillin tested against Enterobacteriaceae and Acinetobacter spp. When linked to a laboratory patient database, the bar code and disc identification facilities avoided errors that were associated with manual data entry.
Subject(s)
Acinetobacter/drug effects , Anti-Bacterial Agents/pharmacology , Enterobacteriaceae/drug effects , Microbial Sensitivity Tests/methods , Drug Resistance, Microbial/physiology , HumansABSTRACT
Anaerobes are often involved in human pathology, including oral infections. The therapy of anaerobic infection requires certain antibiotics such as: metronidazole, tetracycline or amoxicillin. But the incidence of resistant strains among anaerobes is continuously increasing and it is necessary to find some new agents effective against these bacteria. The aim of our study was to establish the bactericidal activity of two new quinolones against 14 strains of gram-negative anaerobic bacilli. The MIC of tested strains was first detected and then time-kill kinetics was determined by using Miles and Misra methodology. Ciprofloxacin was used as standard-quinolone. The results show that trovafloxacin and moxifloxacin have good activity against anaerobes, better than that of ciprofloxacin. Bactericidal curves suggest a rapid action of moxifloxacin (within the first 4 hours), but a prolonged cidal activity for trovafloxacin (24 hours). For both agents, the antimicrobial effect is concentration-dependent. As previous studies suggest, the new quinolones have good activity against both aerobic and anaerobic bacteria so they are useful in the treatment of mixed infections (common feature of anaerobic infections).
Subject(s)
Anti-Infective Agents/pharmacology , Aza Compounds , Ciprofloxacin/pharmacology , Fluoroquinolones , Gram-Negative Anaerobic Straight, Curved, and Helical Rods/drug effects , Naphthyridines/pharmacology , Quinolines , Bacteroides fragilis/drug effects , Fusobacterium/drug effects , Humans , Microbial Sensitivity Tests , Moxifloxacin , Porphyromonas/drug effects , Prevotella/drug effectsABSTRACT
The time-kill kinetics and post-antibiotic effect (PAE) of moxifloxacin were studied for strains of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus and Escherichia coli. Moxifloxacin had a bactericidal effect against all strains tested, with the least rapid bactericidal effect being against S. pyogenes and the most rapid effect against S. aureus and E. coli. The PAE of moxifloxacin was similar to that of other fluoroquinolones and increased with increasing concentration. No association was found between the bactericidal effect of moxifloxacin and the duration of PAE. Gram-positive and gram-negative organisms were also exposed to concentrations of moxifloxacin, sparfloxacin and amoxycillin that simulated the drug concentrations obtained in human serum after standard oral dosing schedules. Simulation of moxifloxacin concentrations in human serum reduced viable counts more effectively and more rapidly than shown in time-kill experiments; in contrast, sparfloxacin and amoxycillin were less effective than when constant concentrations of these antibacterials were used.
Subject(s)
Anti-Infective Agents/pharmacology , Aza Compounds , Fluoroquinolones , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Quinolines , Drug Resistance, Microbial , Escherichia coli/drug effects , Haemophilus influenzae/drug effects , Humans , Microbial Sensitivity Tests , Moxifloxacin , Serum Bactericidal Test , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Streptococcus pyogenes/drug effectsABSTRACT
The widespread, frequent clinical use of the macrolides and quinolones has led to resistance in several species. With the prevailing increase of resistance, new developmental compounds with improved spectra, pharmacokinetics, and reduced adverse effects are required, coupled with logical use of the current armamentarium.
Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , 4-Quinolones , Anti-Bacterial Agents/chemistry , Anti-Infective Agents/chemistry , Bacteroides fragilis/drug effects , Chlamydophila pneumoniae/drug effects , DNA Topoisomerases, Type II/drug effects , Drug Resistance, Microbial/physiology , Genes, Bacterial/physiology , Gram-Negative Aerobic Rods and Cocci/drug effects , Gram-Negative Aerobic Rods and Cocci/genetics , Gram-Positive Cocci/drug effects , Gram-Positive Cocci/genetics , Haemophilus influenzae/drug effects , Legionella pneumophila/drug effects , Macrolides , Mutation/drug effects , Mycoplasma pneumoniae/drug effects , Structure-Activity RelationshipABSTRACT
The pharmacodynamic properties of a novel ketolide (a new class of macrolide), HMR 3647, were investigated by studying time-kill kinetics and postantibiotic effect (PAE). The time-kill kinetics were studied at two inocula against three strains each of Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium and Bacteroides fragilis. The PAEs of HMR 3647 were also investigated on these organisms at concentrations equivalent to 1, 4 and 10 x MIC. The time-kill kinetic data demonstrated that HMR 3647 is predominantly bacteriostatic and only slowly bactericidal at higher concentrations. HMR 3647 exhibited a significant PAE with all strains studied, ranging from 1.2 h to 8.2 h at 10 x MIC. The bacteriostatic activity and significant PAE demonstrated by HMR 3647 are similar to those previously obtained with other macrolides.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteroides fragilis/drug effects , Enterococcus/drug effects , Ketolides , Macrolides , Respiratory Tract Infections/microbiology , Anti-Bacterial Agents/pharmacokinetics , Haemophilus influenzae/drug effects , Kinetics , Microbial Sensitivity Tests , Moraxella catarrhalis/drug effects , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Time FactorsABSTRACT
The in-vitro activity of HMR 3647, a novel ketolide, was investigated in comparison with those of erythromycin A, roxithromycin, clarithromycin (14-membered ring macrolides), amoxycillin-clavulanate and ciprofloxacin against 719 recent clinical Gram-positive, Gram-negative and anaerobic isolates and type cultures. HMR 3647 generally demonstrated greater activity than the other compounds with MIC90s of < or =0.5 mg/L, except for Staphylococcus epidermidis (MIC90 > 128 mg/L), Haemophilus influenzae (MIC90 = 2 mg/L), Enterococcus faecalis (MIC90 = 2 mg/L), Enterococcus faecium (MIC90 = 1 mg/L) and the anaerobes, Bacteroides fragilis (MIC90 = 2 mg/L) and Clostridium difficile (MIC90 = 1 mg/L). In general, an increase in the size of the inoculum from 10(4) to 10(6) cfu on selected strains had little effect on the MICs of HMR 3647. Additionally, the in-vitro activity of HMR 3647 was not affected by the presence of either 20 or 70% (v/v) human serum. The antichlamydial activity of HMR 3647 was generally greater than that of commonly used antichlamydial antimicrobials.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacterial Infections/microbiology , Ketolides , Macrolides , Anti-Infective Agents/pharmacology , Chlamydia/drug effects , Chlamydia Infections/microbiology , Ciprofloxacin/pharmacology , Humans , Lactams/pharmacology , Microbial Sensitivity Tests , Serum Bactericidal TestABSTRACT
The in-vitro activity of linezolid, a novel oxazolidinone, was investigated in comparison with those of amoxycillin, cefuroxime, quinupristin/dalfopristin, trovafloxacin and vancomycin against 420 recent Gram-positive and anaerobic clinical isolates. Linezolid was equally active (MIC90 1 mg/L) against methicillin-susceptible and -resistant Staphylococcus aureus. It demonstrated uniform activity against streptococci and enterococci and no cross-resistance with other agents. The time-kill kinetic data demonstrated that the in-vitro activity of linezolid was predominantly bacteriostatic; slow bactericidal activity was only observed at the higher concentration with streptococci. An increase in inoculum from 10(4) to 10(6) cfu on selected strains had little effect on the MICs (MIC90 within one dilution step) of linezolid and an increase in inoculum from 10(5) to 10(7) cfu/mL had no notable effect on the in-vitro bactericidal activity. A tentative linezolid breakpoint of 2 mg/L was chosen after analysis of distribution of susceptibilities.
Subject(s)
Acetamides/pharmacology , Anti-Bacterial Agents/pharmacology , Bacteria, Anaerobic/drug effects , Bacteroides fragilis/drug effects , Gram-Positive Bacteria/drug effects , Oxazoles/pharmacology , Oxazolidinones , Bacteroides Infections/microbiology , Colony Count, Microbial , Gram-Positive Bacterial Infections/microbiology , Humans , Linezolid , Microbial Sensitivity Tests , Time FactorsABSTRACT
We assessed the post-antibiotic effect (PAE) of azithromycin against 3 strains of Streptococcus pneumoniae 2 strains of Haemophilus influenzae and 2 strains of Moraxella catarrhalis. The strains were exposed for 2 hours to a concentration of 0.5 mg/l. A stationary phase inoculum of 1 x 10(6)-5 x 10(6) CFU/ml in IsoSensitest Broth with 5% lysed horse blood and 20 mg/l NAD was used and shaken for the duration of the experiment. Antibiotic was neutralised by dilution 1:1000 into pre-warmed medium. [table: see text] In conclusion, even at such low concentration as achieved in serum, azithromycin has a PAE against the respiratory pathogens studied. In our opinion this could allow the use of azithromycin, in the usual regimen even in bacteremic respiratory infections.
Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Bacteria/drug effects , Bacterial Infections/microbiology , Respiratory Tract Infections/microbiology , Dose-Response Relationship, Drug , Humans , Microbial Sensitivity Tests , Time FactorsABSTRACT
OBJECTIVE: The pharmacodynamic properties of the novel ketolide (a new class of macrolide) antibiotic, HMR 3004, were investigated by studying time-kill kinetics and postantibiotic effect. METHODS: The time-kill kinetics were studied at two inocula against three strains each of Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium and Bacteroides fragilis. The postantibiotic effects of HMR 3004 were also investigated on these organisms at concentrations equivalent to 1, 4 and 10 x MIC. RESULTS: The time kill-kinetic data demonstrated that HMR 3004 is inoculum dependent and predominantly bacteriostatic being only slowly bactericidal at higher concentrations. HMR 3004 exhibited a significant postantibiotic effect with all strains studied, ranging from 1.9--6.2 h at 10 x MIC. CONCLUSIONS: The bacteriostatic activity and significant postantibiotic effect demonstrated by HMR 3004 are similar to those previously obtained with other macrolides.
ABSTRACT
The postantibiotic effect (PAE) of trovafloxacin (CP 99,219) was investigated with six strains of Pseudomonas aeruginosa at concentrations equivalent to 0.5, 1, 2 and 4 x MIC. Trovafloxacin exhibited a significant PAE with four out of the six strains of P. aeruginosa studied. The PAE values obtained for trovafloxacin with P. aeruginosa ranged from 0.3 h to 2.3 h, increasing with increased exposure time and trovafloxacin concentration.
Subject(s)
Anti-Infective Agents/pharmacology , Fluoroquinolones , Naphthyridines/pharmacology , Pseudomonas aeruginosa/drug effects , Microbial Sensitivity Tests , Pseudomonas aeruginosa/metabolism , Time FactorsABSTRACT
Time-kill kinetics of BAY 12-8039 were studied at two inocula against three strains each of Bacteroides fragilis, Escherichia coli, Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pyogenes. The postantibiotic effects of BAY 12-8039 were studied on three strains each of E. coli, S. aureus, H. influenzae, Streptococcus pyogenes, and Streptococcus pneumoniae. The pharmacodynamic data demonstrated that BAY 12-8039 has marked activity against gram-positive and gram-negative organisms (under both anaerobic and aerobic conditions) and anaerobes. BAY 12-8039 also exhibited a postantibiotic effect of >1 h for all strains except one E. coli strain.
Subject(s)
Anti-Infective Agents/pharmacology , Aza Compounds , Fluoroquinolones , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Quinolines , Quinolones/pharmacology , Microbial Sensitivity Tests , Moxifloxacin , Quinolones/pharmacokineticsABSTRACT
Some strains of staphylococci have raised MBCs of quinupristin/dalfopristin compared with their MICs. In this study, the time-kill kinetics of quinupristin/dalfopristin at 2 mg/L on two strains of Staphylococcus aureus were determined by viable count and intracellular ATP measurement. After 24 h exposure to quinupristin/dalfopristin, the percentage survival of the strain with a raised MBC was 5.9 and that of the strain with a normal MBC was 0.04. The time-kill kinetics of the strain with a raised MBC were analogous to those associated with phenotypic tolerance.
Subject(s)
Anti-Bacterial Agents/pharmacology , Staphylococcus aureus/drug effects , Virginiamycin/pharmacology , Colony Count, Microbial , Microbial Sensitivity Tests/methods , Staphylococcus aureus/growth & development , Time FactorsABSTRACT
The pharmacodynamic properties of faropenem, a new oral penem antibiotic, were investigated by studying time-kill kinetics and postantibiotic effect. Time-kill kinetics were employed against strains of Bacteroides fragilis, Escherichia coli, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes. The postantibiotic effects of faropenem were studied using strains of E. coli, S. aureus, H. influenzae and Streptococcus pneumoniae. The time-kill kinetic data demonstrated that faropenem has bactericidal activity. Faropenem exhibited a significant postantibiotic effect against all strains except H. influenzae.
Subject(s)
Anti-Bacterial Agents/pharmacology , Lactams , Bacteroides fragilis/drug effects , Escherichia coli/drug effects , Haemophilus influenzae/drug effects , Kinetics , Microbial Sensitivity Tests , Moraxella catarrhalis/drug effects , Staphylococcus aureus/drug effects , Streptococcus pyogenes/drug effects , Time Factors , beta-LactamsABSTRACT
The in vitro activity of BAY 12-8039, a new fluoroquinolone, was studied in comparison with those of ciprofloxacin, trovafloxacin (CP 99,219), cefpodoxime, and amoxicillin-clavulanate against gram-negative, gram-positive, and anaerobic bacteria. Its activity against mycobacteria and chlamydia was also investigated. BAY 12-8039 was active against members of the family Enterobacteriaceae (MIC at which 90% of strains tested were inhibited [MIC90S] < or = 1 microgram/ml, except for Serratia spp. MIC90 2 microgram/ml), Neisseria spp. (MIC90S, 0.015 microgram/ml), Haemophilus influenzae (MIC90, 0.03 microgram/ml), and Moraxella catarrhalis (MIC90, 0.12 micrgram/ml), and these results were comparable to those obtained for ciprofloxacin and trovafloxacin. Against Pseudomonas aeruginosa, the quinolones were more active than the beta-lactam agents but BAY 12-8039 was less active than ciprofloxacin. Strains of Stenotrophomonas maltophilia were fourfold more susceptible to BAY 12-8039 and trovafloxacin (MIC90S, 2 micrograms/ml) than to ciprofloxacin. BAY 12-8039 was as active as trovafloxacin but more active than ciprofloxacin against Streptococcus pneumoniae (MIC90, 0.25 microgram/ml) and methicillin-susceptible Staphylococcus auerus (MIC90S, 0.12 micrograms/ml). The activity of BAY 12-8039 against methicillin-resistant S. aureus (MIC90, 2 micrograms/ml) was lower than that against methicillin-susceptible strains. BAY 12-8039 was active against anaerobes (MIC90S < or = 2 micrograms/ml), being three- to fourfold more active against Bacteroides fragilis, Prevotella spp., and Clostridium difficile than was ciprofloxacin. Against Mycobacterium tuberculosis, BAY 12-8039 exhibited activity comparable to that of rifampin (MICs < or = 0.5 micrograms/ml). Against Chlamydia trachomatis and Chlamydia pneumoniae BAY 12-8039 was more active (MICs < or = 0.12 microgram/ml) than either ciprofloxacin or erythromycin and exhibited a greater lethal effect than either to these two agents. The protein binding of BAY 12-8039 was determined at 1 and 5 micrograms/ml as 30 and 26.4%, respectively. The presence of human serum (at 20 or 70%) had no marked effect on the in vitro activity of BAY 12-8039.
Subject(s)
Anti-Infective Agents/pharmacology , Aza Compounds , Bacteria, Anaerobic/drug effects , Fluoroquinolones , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Quinolines , Quinolones/pharmacology , Anti-Infective Agents/chemistry , Drug Resistance, Microbial , Humans , Microbial Sensitivity Tests , Moxifloxacin , Protein Binding , Quinolones/chemistryABSTRACT
Azithromycin has in vitro activity which includes important respiratory pathogens and is successful in treatment of respiratory tract infections. We assessed postantibiotic effect (PAE) of azithromycin against 3 stains of Streptococcus pneumoniae, 2 strains of Haemophilus influenzae and 2 strains of Moraxella catarrhalis. The strains were exposed for 2 hours to an azithromycin concentration of 0.5 mg/L (maximum serum concentration achieved by azithromycin after the usual dosing regimen). A stationary phase inoculum of 1 x 10(6)-5 x 10(6) UFC/ml in IsoSensitest Broth with 5% lysed horse blood and 20 mg/L NAD was used and shaken for the duration of the experiment. Antibiotic was neutralised by dilution 1:1000 into pre-warmed medium. Viable counts were determined before and after antibiotic exposure and then hourly for 7 hours by Miles and Misra method. The experiment was performed in triplicate. Even at such low concentration as that achieved in serum, azithromycin exhibits a PAE of 119 min for pneumococci, 130 min for haemophili and 155 min for moraxellae, fact which could allow the use of usual oral regimen in bacteraemic respiratory infection, as well.